arrow
B

Benjamin Mercier

city of hope comprehensive cancer center
H指数:7
被引数:226

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

18 Prediction of Immune-Related Adverse Events (irAEs) with Hematologic Markers in Patients Receiving First-Line Immune Checkpoint Inhibitor (ICI)-Based Therapy in Metastatic Renal Cell Carcinoma (mRCC)

18 预测接受一线免疫检查点抑制剂(ICI)治疗的转移性肾细胞癌(mRCC)患者中,利用血液学标志物预测免疫相关不良事件(irAEs)

2026-09-020
OAAI
Evaluating Worldwide Disparities in Bladder Cancer Clinical Trial Availability

评估全球范围内膀胱癌临床试验可及性的差异

Cancers
IF4.4
2026-05-270
OA
Clinical Predictors and Prognostic Significance of Pathologic Disease Upstaging at Radical Cystectomy in Patients with Muscle-Invasive Bladder Cancer

肌层浸润性膀胱癌患者根治性膀胱切除术中病理疾病升级的临床预测因素及预后意义

2025-10-090
OA
Efficacy and safety of antibody-drug conjugate combination therapy in advanced urothelial carcinoma

抗体药物偶联物联合疗法在晚期尿路上皮癌中的疗效与安全性

2025-10-070
OAAI
VHL and TP53 mutation status are not associated with response or progression-free survival in metastatic renal cell carcinoma treated with VEGF-targeted therapies

VHL和TP53突变状态与接受VEGF靶向治疗的转移性肾细胞癌的治疗反应或无进展生存期无关。

2025-10-010
OAAI
Exploring Health-Related quality of life across the disease spectrum in renal cell carcinoma: a conceptual domain analysis

探索肾细胞癌疾病谱中健康相关生命质量的领域分析

2025-10-010
OA
Characterization of aberrant alternative splicing landscape in patients with metastatic renal cell carcinoma

转移性肾细胞癌患者中异常替代剪接景观的特征分析

2025-10-010
OAAI
Real-World evidence shows no survival advantage with contemporary first-line strategies in papillary renal cell carcinoma: a call for randomized trials

真实世界证据表明,在乳头状肾细胞癌中,当代一线策略并未显示出生存优势:呼吁开展随机试验

2025-10-010
OA
Clinical and Pathological Predictors for Occult Lymph Node Involvement in Patients With Clinical Node-Negative Bladder Cancer Undergoing Radical Cystectomy

临床和病理学预测因子:在接受根治性膀胱切除术的临床淋巴结阴性的膀胱癌患者中 occult 淋巴结受累的预测因子

2025-09-010
PRE
Development of a Health-related Quality of Life Questionnaire for Patients with Metastatic or Localized Renal Cell Carcinoma

为转移性或局限性肾细胞癌患者开发健康相关生活质量问卷

2025-08-190
PRE
Comprehensive tumor-immune profiling reveals mediators of paradoxical immune sensitivity in sarcomatoid renal cell carcinoma

全面肿瘤-免疫谱分析揭示了肉瘤样肾细胞癌中矛盾性免疫敏感性的介导因子

2025-08-070
PREAI
Eligibility Criteria in Advanced Urothelial Cancer Clinical Trials: An Assessment of Modernization and Inclusion

晚期尿路上皮癌临床试验的纳入标准:现代化与包容性的评估

2025-03-270
OAAI
Impact of Synchronous versus Metachronous Metastasis on Outcomes in Patients with Metastatic Renal Cell Carcinoma Treated with First-line Immune Checkpoint Inhibitor-based Combinations
2024-09-010
OAAI
Cabozantinib and nivolumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial

卡博替尼和nivolumab联合或不联合活细菌补充治疗转移性肾细胞癌: 一项随机1期试验

2024-06-285
OAAI
Prevalence of Dietary Modification and Supplement Use in Patients with Metastatic Renal Cell Carcinoma Receiving Systemic Therapy
2024-05-260
OAAI
Assessment of eligibility criteria in renal cell carcinoma trials evaluating systemic therapy
2023-09-011
OAAI
Characterization of papillary and clear cell renal cell carcinoma through imaging mass cytometry reveals distinct immunologic profiles

通过成像质量细胞术表征乳头状和透明细胞肾细胞癌揭示了不同的免疫学特征

2023-08-113
OAAI
Genomic and Transcriptomic Predictors of Response from Stereotactic Body Radiation Therapy in Patients with Oligoprogressive Renal Cell Carcinoma

寡进展性肾细胞癌患者立体定向放射治疗反应的基因组和转录组学预测因子

2023-08-013
PRE